ASX - By Stock
|
PAR |
Re:
Potential Financial Implications of Yesterday's Results
|
|
adherent
|
97 |
44K |
6 |
05/10/22 |
05/10/22 |
ASX - By Stock
|
97
|
44K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
adherent
|
115 |
64K |
10 |
05/10/22 |
05/10/22 |
ASX - By Stock
|
115
|
64K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
adherent
|
115 |
64K |
27 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
115
|
64K
|
27
|
|
ASX - By Stock
|
PAR |
Re:
PAR stock price - what should today's value be?
|
|
adherent
|
36 |
18K |
13 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
36
|
18K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
1 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
adherent
|
115 |
59K |
29 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
115
|
59K
|
29
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
adherent
|
104 |
41K |
16 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
41K
|
16
|
|
ASX - By Stock
|
PAR |
Re:
Luck favors the lucky ones.
|
|
adherent
|
12 |
5.9K |
0 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
12
|
5.9K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
6 |
22/09/22 |
22/09/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Luck favors the lucky ones.
|
|
adherent
|
12 |
5.9K |
24 |
22/09/22 |
22/09/22 |
ASX - By Stock
|
12
|
5.9K
|
24
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
adherent
|
670 |
260K |
15 |
22/09/22 |
22/09/22 |
ASX - By Stock
|
670
|
260K
|
15
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
6 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
6
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
31 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
31
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
adherent
|
109 |
39K |
11 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
109
|
39K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
adherent
|
109 |
39K |
25 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
109
|
39K
|
25
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
13 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
13
|
|
ASX - By Stock
|
PAR |
Re:
PAR stock price - what should today's value be?
|
|
adherent
|
36 |
18K |
23 |
05/09/22 |
05/09/22 |
ASX - By Stock
|
36
|
18K
|
23
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
adherent
|
670 |
260K |
3 |
03/09/22 |
03/09/22 |
ASX - By Stock
|
670
|
260K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
adherent
|
670 |
260K |
17 |
03/09/22 |
03/09/22 |
ASX - By Stock
|
670
|
260K
|
17
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
6 |
31/08/22 |
31/08/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
6
|
|
ASX - By Stock
|
PAR |
Re:
The novel drug - A DMOAD approach
|
|
adherent
|
36 |
14K |
0 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
36
|
14K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Presentation - $66m Capital Raise
|
|
adherent
|
87 |
35K |
19 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
87
|
35K
|
19
|
|
ASX - By Stock
|
PAR |
Re:
The novel drug - A DMOAD approach
|
|
adherent
|
36 |
14K |
22 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
36
|
14K
|
22
|
|
ASX - By Stock
|
PAR |
Re:
The novel drug - A DMOAD approach
|
|
adherent
|
36 |
14K |
18 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
36
|
14K
|
18
|
|
ASX - By Stock
|
PAR |
Re:
WTF- what's with the share price movement
|
|
adherent
|
129 |
60K |
9 |
09/08/22 |
09/08/22 |
ASX - By Stock
|
129
|
60K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
The novel drug - A DMOAD approach
|
|
adherent
|
36 |
14K |
31 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
36
|
14K
|
31
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
3 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
'Something Cool is Coming'
|
|
adherent
|
22 |
9.7K |
7 |
11/07/22 |
11/07/22 |
ASX - By Stock
|
22
|
9.7K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
adherent
|
4.2K |
3.8M |
10 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Reports Australian Patent Acceptance
|
|
adherent
|
64 |
24K |
32 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
64
|
24K
|
32
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
10 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
10
|
|
ASX - By Stock
|
PAR |
Re:
The Heartfelt addressing...
|
|
adherent
|
10 |
5.0K |
7 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
10
|
5.0K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
4 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
4
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
2 |
11/06/22 |
11/06/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
The stairway to heaven
|
|
adherent
|
13 |
6.6K |
26 |
07/06/22 |
07/06/22 |
ASX - By Stock
|
13
|
6.6K
|
26
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
13 |
05/06/22 |
05/06/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Appoints Experienced US-Based CEO
|
|
adherent
|
82 |
32K |
20 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
82
|
32K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Appoints Experienced US-Based CEO
|
|
adherent
|
82 |
32K |
12 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
82
|
32K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Appoints Experienced US-Based CEO
|
|
adherent
|
82 |
32K |
4 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
82
|
32K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
iPPS and Inflammation
|
|
adherent
|
8 |
3.7K |
0 |
17/05/22 |
17/05/22 |
ASX - By Stock
|
8
|
3.7K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
0 |
14/05/22 |
14/05/22 |
ASX - By Stock
|
76
|
36K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
4 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
76
|
36K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
0 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
76
|
36K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
28 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
76
|
36K
|
28
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
3 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
76
|
36K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
1 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
76
|
36K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
26 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
76
|
36K
|
26
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
7 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
36K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
17 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
36K
|
17
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
36K |
9 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
36K
|
9
|
|